2Foster CA, Mechtcheriakova D, Storch MK, et al. FRY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol, 2009, 19:254-266.
3Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720) : discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov, 2010, 9:883-897.
4Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem, 2002, 277:21453-21457.
5Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med, 2006, 355:1124- 1140.
6Comi G, O'Connor P, Montalban X, et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Muh Scler, 2010, 16 : 197-207.
7Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med, 2010, 362:387401.
8Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med, 2010, 362:402415.
9Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1 a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol, 2011, 10:520-529.
10Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, 2008, 372:1463-1472.
3Schwartz M. Optic nerve crush: protectionandregeneration[J]. Brain Res Bu11,2004,62(6):467-471.
4Nalcaci E, Basar-Eroglu C, Stadler M. Visual evoked potential interhemispheric transfer time in different frequency bands[J]. Clin Neurophysiol, 1999,110(1) :71-81.
5Gregori B,Galie E,Pro S,et al. Luminance and chromatic visu- al evoked potentials in type I and II diabetes: relationships with peripheral neuropathy[J]. Neurol Sci, 2006,27 ( 5 ) . 323- 327.
6Gundogan FC, Mutlu FM, Altinsoy HI, et al. Patternvisual e- voked potentials in the assessment of objective visual acuity in amblyopic children[J]. Int Ophthalmol, 2010,30(4) : 377-383.
7Hamilton R, Bradnam MS, Dutton GN, et al. Sehsitivity and specificity of the step VEP in suspected functional visual acui- ty loss[J]. Doc Ophthalmol,2013,126(2) :99-104.
8Neveu MM,Jeffery G, Burton LG, et al. Age-related changes in the dynamics of human albino visual pathways[J]. Eur J Neurosci, 2003,18(7) : 1939-1949.
9Zhilin G, H uoniu O, Zhihua C, et al. Wide optic nerve canal decom- pressionfor the treatment of blindness resulting froman indirect opticnerveinjury[J]. J Craniofac Surg, 2011,22 : 1463.
